Prothena CORP Public LTD CO Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
William P Scully, a 10% owner of Prothena Corp Public Ltd Co, reported a transaction in 251,553 shares of common stock on August 10, 2026.
NASDAQ
William P Scully, a 10% owner of Prothena Corp Public Ltd Co, purchased 37,500 shares of common stock on August 7, 2026 for $8.62 per share.
NASDAQ
Wagner M. Zago, Chief Scientific Officer of Prothena Corp Public Ltd Co, reported multiple transactions in common stock on July 28, 2026.
NASDAQ
Karin L Walker, Chief Accounting Officer of Prothena Corp Public Ltd Co, reported multiple transactions in common stock on July 28, 2026.
NASDAQ
Chad J. Swanson, Chief Development Officer of Prothena Corp Public Ltd Co, reported multiple transactions in common stock on July 28, 2026.
NASDAQ
Brandon S. Smith, Chief Operating Officer of Prothena Corp Public Ltd Co, reported multiple transactions in common stock on July 28, 2026.
NASDAQ
Tran Nguyen, Chief Strategy Officer and CFO of Prothena Corp Public Ltd Co, reported multiple transactions in common stock on July 28, 2026.
NASDAQ
Gene G. Kinney, President and CEO and a Director of Prothena Corp Public Ltd Co, reported multiple transactions in common stock on July 28, 2026.
NASDAQ
Anne Evans Kingston, Chief Strategy Officer of Prothena Corp Public Ltd Co, sold 7,662 shares of common stock on July 28, 2026 for $8.47 per share.
NASDAQ
Michael John Isaacs, General Counsel & Company Sec. of Prothena Corp Public Ltd Co, sold 8,386 shares of common stock on July 28, 2026 for $8.47 per share.
NASDAQ
William P. Scully, a Director at Prothena Corp, has acquired 20,000 ordinary shares in a series of transactions.
NASDAQ
Reporting person William P. Scully gifted 325,000 ordinary shares of Prothena Corp, reducing his direct holdings.
NASDAQ
10% owner William P. Scully acquired 125,000 shares of Prothena Corp at a weighted average price of $8.1698.
NASDAQ
10% owner William P. Scully acquired 50,000 shares of Prothena Corp at a weighted average price of $9.3059.
NASDAQ
Director William P. Scully of Prothena Corp Public Ltd Co acquired 50,000 ordinary shares in a transaction on June 2, 2026.
NASDAQ
Director William P. Scully acquired 100,000 ordinary shares of Prothena Corp Public Ltd Co for approximately $9.81 per share.
NASDAQ
Director Daniel G. Welch was granted 27,000 stock options in Prothena Corporation as part of standard equity compensation.
NASDAQ
Director Dennis J. Selkoe was granted 27,000 stock options in Prothena Corporation as part of standard director compensation.
NASDAQ
Director Lars Ekman was granted 27,000 stock options in Prothena Corporation as part of standard equity compensation.
NASDAQ
Director William H. Dunn Jr. was granted 27,000 stock options in Prothena Corporation as part of standard equity compensation.
NASDAQ
Prothena Corporation director Shane Cooke was granted 27,000 stock options as part of standard equity compensation.
NASDAQ
Director Richard T. Collier was granted 27,000 stock options in Prothena Corporation as part of standard equity compensation.
NASDAQ
Anne Evans Kingston, Chief Strategy Officer at Protana Corp., was granted 100,000 stock options with an exercise price of $10.50, vesting over four years.
NASDAQ
Prothena's Chief Scientific Officer, Wagner M. Zago, was granted 190,000 stock options with an exercise price of $9.36, vesting over four years.
NASDAQ
Prothena's Chief Accounting Officer, Karin L. Walker, reported the acquisition of 150,000 stock options with an exercise price of $9.36.
NASDAQ
Prothena's Chief Development Officer, Chad J. Swanson, was granted 190,000 stock options with an exercise price of $9.36, vesting over four years.
NASDAQ
Prothena's Chief Operating Officer, Brandon S. Smith, was granted 190,000 stock options with an exercise price of $9.36, vesting over four years.
NASDAQ
Prothena Corp Public Ltd Co's Chief Strategy Officer and CFO, Tran Nguyen, was granted 230,000 stock options with a vesting schedule tied to continued employment.
NASDAQ
Prothena Corp Public Ltd Co's Chief Legal Officer, Michael J. Malecek, was granted 190,000 stock options with an exercise price of $9.36, vesting over four years.
NASDAQ
Prothena's President and CEO, Gene G. Kinney, was granted 520,000 stock options with an exercise price of $9.36, vesting over a four-year period.